Retraction notice to "Novel fabrication of Cu(II)-incorporated chiral d-penicillamine-chitosan nanocomposites enantio-selectively inhibit the induced amyloid β aggregation for Alzheimer's disease therapy" [Heliyon 10 (2024) e23563].
Saved in:
| Title: | Retraction notice to "Novel fabrication of Cu(II)-incorporated chiral d-penicillamine-chitosan nanocomposites enantio-selectively inhibit the induced amyloid β aggregation for Alzheimer's disease therapy" [Heliyon 10 (2024) e23563]. |
|---|---|
| Authors: | Zhao F; Department of Neurology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210012, China., Yang H; School of Nursing, Nanjing University of Chinese Medicine, Nanjing 210023, China., Gao Z; Department of Neurology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210012, China., Liu H; School of Nursing, Nanjing University of Chinese Medicine, Nanjing 210023, China., Wu P; School of Nursing, Nanjing University of Chinese Medicine, Nanjing 210023, China., Li B; School of Nursing, Nanjing University of Chinese Medicine, Nanjing 210023, China., Yu H; Department of Neurology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210012, China., Shao J; Department of Neurology, Wenling First People's Hospital Affiliated to Wenzhou Medical University, Wenling 317500, China. |
| Source: | Heliyon [Heliyon] 2025 Nov 12; Vol. 11 (16), pp. e44134. Date of Electronic Publication: 2025 Nov 12 (Print Publication: 2025). |
| Publication Type: | Journal Article; Retraction Notice |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101672560 Publication Model: eCollection Cited Medium: Print ISSN: 2405-8440 (Print) Linking ISSN: 24058440 NLM ISO Abbreviation: Heliyon Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
